Recombinant human thrombin (Suzhou Zelgen Biopharmaceutical)

外用重组人凝血酶（CHO细胞）（泽璟生物）

Report date: 2024/01/09 09:57:16

Base Information

Drug NameRecombinant human thrombin (Suzhou Zelgen Biopharmaceutical)

Drug Alias NamerhThrombin - Suzhou Zelgen BiopharmaceuticalsZepning

ClassificationBiologics > Protein drugs > Enzyme > Recombinant enzymeBiologics > Protein drugs > Recombinant protein > Recombinant enzymeBiologics > Biosimilar

Mechanisms of ActionThrombin replacementsFibrinogen stimulants

TargetsFibrinogen

Therapy Area/IndicationsBlood Loss, SurgicalHemorrhage

Global Approved IndicationsBlood Loss, Surgical

Approved Indications in ChinaBlood Loss, Surgical

Original Approved Country/TerritoryMainland China

Original Approved Date2023/12/26

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusApproved

Highest Status in ChinaApproved

Originator CompaniesSuzhou Zelgen Biosciences Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesSuzhou Zelgen Biopharmaceuticals Co Ltd

Inactive CompaniesN/A

Active IndicationsBlood Loss, Surgical

Inactive IndicationsHemorrhage

Other Information

ATC CodeN/A